Table 2 Estimated cervical cancer cases and deaths averted for optimal pathway versus status quo

2021–2030

104,684 (92,294 to 117,425)

79,967 (69,927 to 89,751)

24,717 (20,495 to 28,791)

32,248 (30,575 to 34,004)

22,986 (21,566 to 24,365)

2031–2040

787,870 (755,292 to 821,308)

617,718 (585,630 to 650,763)

170,151 (150,964 to 188,778)

223,549 (215,113 to 232,653)

172,801 (164,115 to 181,471)

2041–2050

1,055,622 (1,010,812 to 1,118,157)

842,780 (800,376 to 897,473)

212,842 (182,616 to 247,162)

343,138 (330,470 to 358,224)

277,800 (264,190 to 292,840)

2051–2060

1,132,932 (1,092,152 to 1,219,614)

873,869 (832,217 to 951,946)

259,064 (227,593 to 299,560)

382,491 (369,713 to 402,859)

305,618 (291,910 to 325,951)

2061–2070

1,137,444 (1,075,807 to 1,227,010)

865,938 (809,346 to 942,036)

271,506 (237,146 to 313,962)

385,328 (369,061 to 408,807)

298,520 (281,708 to 319,957)

2071–2080

1,118,296 (1,020,789 to 1,256,136)

840,715 (759,702 to 943,881)

277,581 (240,072 to 330,623)

379,921 (352,929 to 418,315)

283,755 (260,544 to 313,656)

2081–2090

1,091,456 (966,871 to 1,291,902)

804,785 (706,821 to 953,063)

286,671 (242,893 to 353,727)

391,759 (353,916 to 465,217)

288,997 (258,995 to 344,650)

2091–2100

1,080,888 (908,727 to 1,307,522)

788,935 (663,914 to 958,552)

291,953 (237,094 to 368,522)

391,439 (345,049 to 482,525)

288,963 (253,299 to 358,500)

Total

7,509,192 (6,922,744 to 8,359,074)

5,714,707 (5,227,933 to 6,387,465)

1,794,485 (1,538,873 to 2,131,125)

2,529,873 (2,366,826 to 2,802,604)

1,939,440 (1,796,327 to 2,161,390)